Dimou Anastasios T, Syrigos Konstantinos N, Saif Muhammad Wasif
Department of Pathology, Yale University School of Medicine. New Haven, CT, USA.
JOP. 2011 Mar 9;12(2):114-6.
Pancreatic adenocarcinoma has repetitively proved refractory to chemotherapy and biologic compounds with only a few drugs offering limited benefit. A number of novel regimens has been tested in phase I trials and reported recently in the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Specifically, a novel mitogen-activated protein kinase kinase (MEK) inhibitor, a connective tissue growth factor inhibitor, a coagulase factor VIIa inhibitor, as well as adenovirus delivery of herpes simplex virus thymidine synthase gene followed by anti-herpetic treatment have all proven to be safe in pancreatic cancer patients. Phase II trials will provide further evidence whether they can become clinically relevant in the future.
胰腺癌反复被证明对化疗和生物化合物具有耐药性，只有少数药物能带来有限的益处。一些新的治疗方案已在I期试验中进行了测试，并于近期在2011年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上进行了报告。具体而言，一种新型丝裂原活化蛋白激酶激酶（MEK）抑制剂、一种结缔组织生长因子抑制剂、一种凝血酶原因子VIIa抑制剂，以及单纯疱疹病毒胸苷激酶基因的腺病毒递送联合抗疱疹治疗，在胰腺癌患者中均已证明是安全的。II期试验将提供进一步证据，证明它们未来是否能在临床上发挥作用。
